<?xml version="1.0" encoding="UTF-8"?>
<p>Initiation of carfilzomib therapy is routinely done with a step‐up dose from 20 mg/m
 <sup>2</sup> to target dose (56 mg/m
 <sup>2</sup> in CARDAMON). To reduce the risk of infusion reactions and adverse events, such as thrombotic microangiopathy occurring on resuming therapy after a break,
 <xref rid="bjh17168-bib-0013" ref-type="ref">
  <sup>13</sup>
 </xref> an urgent safety measure was implemented. Where carfilzomib maintenance was delayed for &gt;4 weeks, treatment was to be restarted at 20 mg/m
 <sup>2</sup> on day 1 of the new cycle before escalating to the full 56 mg/m
 <sup>2</sup> or last tolerated dose.
</p>
